CD274 and lymphoma: Atezolizumab, a PD-L1 inhibitor, scarcely tested as monotherapy in lymphoma ([59], NCT03120676), is currently being investigated in combination with a BeGEV regimen (bendamustine, gemcitabine and vinorelbine) (NCT05300282) (Table 3).